Close Menu
iM.NewsiM.News

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 2026
    Facebook X (Twitter) Instagram
    iM.NewsiM.News
    Subscribe
    • Home
    • Lifestyle

      US, Mexico, Bolivia Lose Measles-Free Status as Global Cases Rise

      November 20, 2026

      The Opera Coat Trend Takes Over Winter Fashion

      November 20, 2026

      New Weight-Loss Drug Cuts Knee Pain in Half for OA Patients

      November 20, 2026

      Robert Pattinson and Suki Waterhouse Redefine Hollywood Power Couples

      November 20, 2026

      Reading Linked to 33% Lower Alzheimer’s Risk, Study Finds

      November 20, 2026
    • Relations

      US Lawmakers Seek Stricter AI Chip Export Controls

      November 20, 2026

      Trump Threatens Tax on US Tech Firms Building AI Data Centers Abroad

      November 20, 2026

      Former US National Security Adviser Jake Sullivan Confronted by Students at MIT

      November 20, 2026

      Xi Jinping’s Restraint: The Power of Not Acting in Shenzhen

      November 20, 2026

      EU and UK to Sign Reset Deal on Trade and Youth Mobility

      November 20, 2026
    • Technology

      Germany Proposes €25 Billion Buyout of TikTok Europe

      November 20, 2026

      AI Supply Chain Leaks 2 Million Secrets in Canary Test

      November 20, 2026

      Google to retire Nest app in January 2027

      November 20, 2026

      Microsoft Link to Windows Adds Second Screen Feature

      November 20, 2026

      Nothing Sets December 8 Date for AI Hardware Reveal

      November 20, 2026
    • Travel & Tourism

      TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

      November 20, 2026

      Oil Spills Threaten UAE and Oman Beaches Amid Hormuz Conflict

      November 20, 2026

      Aer Lingus to Retrofit A330 Fleet with Premium Economy and New Business Class

      November 20, 2026

      Sabre Targets AI Travel Bookings With New Connector

      November 20, 2026

      Riyadh Hotel Revenue Plummets 65% After Airport Attack

      November 20, 2026
    • Get in Touch
    iM.NewsiM.News
    Home»Lifestyle»Health»FDA Approves First Plasmid DNA Immunotherapy for RRP
    Health

    FDA Approves First Plasmid DNA Immunotherapy for RRP

    im.newsBy im.newsOctober 31, 2026No Comments3 Mins Read15 Views
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Voceryq plasmid DNA immunotherapy vial and CELLECTRA device for recurrent respiratory papillomatosis treatment
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    The U.S. Food and Drug Administration has granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), marking the first time a plasmid DNA-based immunotherapy has been authorized for use in the United States. The treatment is indicated for adults diagnosed with recurrent respiratory papillomatosis, a rare and chronic disease caused by human papillomavirus (HPV) that results in the formation of wart-like growths within the airways.

    Targeting the Root Cause of RRP

    Recurrent respiratory papillomatosis is driven by HPV types 6 and 11. These viruses cause papillomas to develop, most commonly around the larynx and vocal cords. The growths can lead to hoarseness, chronic cough, and in severe instances, breathing difficulties. While surgical removal is the standard care, it does not cure the underlying infection. The virus remains in the tissue, often necessitating repeated procedures over many years to manage symptoms and prevent airway obstruction.

    Voceryq operates differently by engaging the body’s immune system to fight the infection at its source. The therapy consists of two plasmids, which are small circular DNA molecules. One plasmid contains genetic instructions for specific HPV proteins, while the other encodes an immune response-enhancing molecule known as IL-12. When introduced into the body, these plasmids instruct cells to produce these proteins, thereby stimulating an immune response against HPV-infected cells.

    The drug is administered via intramuscular injection using the CELLECTRA 5PSP Device. This device facilitates electroporation, a process that uses brief electrical pulses to create temporary pores in cell membranes. This technique allows the plasmid DNA to enter the cells more effectively than standard injection methods alone.

    Clinical Trial Results and Safety Profile

    The approval was based on data from an open-label, multicenter clinical trial involving 32 adults with recurrent respiratory papillomatosis. Participants had undergone at least two surgeries to remove laryngotracheal papillomas in the 12 months prior to starting the treatment. The study focused on an intermediate clinical endpoint: the reduction in the frequency of surgical interventions required.

    Among the 26 patients who had undergone at least three baseline surgeries, seven, or 27 percent, did not require any surgical intervention during the first year following Voceryq treatment. The FDA noted that this reduction in surgical burden is reasonably likely to predict clinical benefit for patients.

    Common adverse reactions reported in the trial included injection site reactions, headache, fatigue, hypertension, nausea, and dizziness. The electroporation procedure itself carries specific risks, such as brief muscle contractions, temporary bleeding at the injection site, anxiety, and vasovagal reactions. Patients may also experience transient changes in creatine phosphokinase levels and skin redness at the administration site.

    Karim Mikhail, director of the Center for Biologics Evaluation and Research at the FDA, highlighted the significance of this approval for a patient population with limited options. He noted that the therapy offers a potential shift from managing symptoms to addressing the underlying cause, which could mean fewer surgeries and less disruption to patients’ lives.

    Inovio Pharmaceuticals, Inc. received the accelerated approval for Voceryq. The company also holds Breakthrough Therapy and Orphan Drug designations for the product from the FDA. Because the approval is granted under the accelerated approval pathway, the manufacturer is required to conduct post-approval clinical trials to verify and describe the drug’s clinical benefit.

    Source: U.S. FDA

    FDA Health HPV immunotherapy Inovio RRP Voceryq
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleBig Tech AI Spending Sparks Market Jitters
    Next Article Disney Lays Off 100-200 Workers in Theme Park Division
    im.news

    Related Posts

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 2026
    Leave A Reply Cancel Reply

    Latest Posts

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 20261 Views

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 20263 Views

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 20262 Views

    US, Mexico, Bolivia Lose Measles-Free Status as Global Cases Rise

    November 20, 20262 Views
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss

    Epstein List Phase 1: Full Flight Logs, Client List Released

    February 28, 2025 News Focus 247 Views

    In a stunning development that has sent shockwaves through political and entertainment circles, Attorney General…

    Microsoft Stock Joins Exclusive $4 Trillion Club After Blockbuster Cloud + AI Earnings

    July 31, 2025

    DOJ & FBI Find No Epstein Client List, Suicide Confirmed

    July 7, 2025

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide the daily life news. You find latest trendy news at our portal, from entertainment to economy or politics.

    We're accepting new partnerships right now.

    Email Us: info@im.news

    Facebook X (Twitter) RSS
    Our Picks

    Curiosity Rover Captures Rare Twilight Clouds on Mars

    November 20, 2026

    US Lawmakers Seek Stricter AI Chip Export Controls

    November 20, 2026

    TAP Air Portugal Adds Nonstop Porto Service from Washington Dulles

    November 20, 2026
    Most Popular

    Epstein List Phase 1: Full Flight Logs, Client List Released

    February 28, 2025247 Views

    Microsoft Stock Joins Exclusive $4 Trillion Club After Blockbuster Cloud + AI Earnings

    July 31, 2025208 Views

    DOJ & FBI Find No Epstein Client List, Suicide Confirmed

    July 7, 2025165 Views
    © 2026 I'm News. Designed by I'm News.
    • Home
    • Lifestyle
    • Relations
    • Travel & Tourism
    • Technology

    Type above and press Enter to search. Press Esc to cancel.